B of A Securities Maintains Buy on BioCryst Pharma, Raises Price Target to $15

Benzinga · 07/01 13:44
B of A Securities analyst Tazeen Ahmad maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and raises the price target from $13 to $15.